EXEL

Exelixis, Inc. Press Releases

$4.2
*  
0.03
0.71%
Get EXEL Alerts
*Delayed - data as of Feb. 11, 2016  -  Find a broker to begin trading EXEL now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    EXEL After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10
2/4/2016 4:05:00 PM - Business Wire
▼-11.58 % Price Change since this news event. The Volume Ratio is 1.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma
2/1/2016 8:00:00 AM - Business Wire
▼-11.58 % Price Change since this news event. The Volume Ratio is 1.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma
1/28/2016 4:05:00 PM - Business Wire
▲0.48 % Price Change since this news event. The Volume Ratio is 1.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma
1/28/2016 8:00:00 AM - Business Wire
▼-4.76 % Price Change since this news event. The Volume Ratio is 1.2.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma
1/11/2016 8:30:00 AM - Business Wire
▼-13.93 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma to be Presented at ASCO 2016 Genitourinary Cancers Symposium
1/4/2016 5:07:00 PM - Business Wire
▼-23.50 % Price Change since this news event. The Volume Ratio is 3.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Covered Call Alerts For Fitbit, Keryx Biopharmaceuticals, SolarEdge Technologies, Chipotle Mexican Grill and Exelixis Released By InvestorsObserver
12/28/2015 9:31:00 AM - PR Newswire
▼-20.60 % Price Change since this news event. The Volume Ratio is 0.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
12/23/2015 8:30:00 AM - Business Wire
▼-14.98 % Price Change since this news event. The Volume Ratio is 2.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Covered Call Alerts For Exelixis, Alleghany Technologies, NVIDIA, Qorvo and Palo Alto Networks Released By InvestorsObserver
12/11/2015 9:31:00 AM - PR Newswire
▼-15.32 % Price Change since this news event. The Volume Ratio is 1.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day











Learn more by visiting our FAQ page